The CBR4 (Carbonyl Reductase 4) antibody targets an enzyme belonging to the short-chain dehydrogenase/reductase (SDR) superfamily. CBR4 is a NADPH-dependent oxidoreductase involved in metabolizing endogenous and exogenous carbonyl compounds, including steroid hormones, prostaglandins, and xenobiotics. It plays a role in drug metabolism, particularly in the reduction of chemotherapeutic agents like doxorubicin, influencing drug efficacy and toxicity. CBR4 is ubiquitously expressed, with higher levels in the liver, kidneys, and certain cancer tissues. Research has linked its overexpression to chemoresistance in cancers, suggesting its potential as a biomarker or therapeutic target. The CBR4 antibody is widely used in biochemical and pathological studies to investigate enzyme localization, expression patterns, and functional roles in metabolic pathways, drug resistance, and disease progression. Its applications span cancer biology, toxicology, and metabolic disorder research, aiding in the development of strategies to modulate enzyme activity for therapeutic benefit. Recent studies also explore its involvement in cellular stress responses and redox regulation, highlighting its broader physiological relevance.